Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Yaribeygi, Habib; Sathyapalan, Thozhukat; Maleki, Mina; Jamialahmadi, Tannaz; Sahebkar, Amirhossein
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a relatively newer class of anti-hyperglycemic medications that reduce blood glucose by inhibition of renal glucose re-uptake, thereby increasing urinary glucose excretion. Although glycosuria is the primary mechanism of action of these agents, there is some evidence suggesting they can reduce insulin resistance and induce peripheral insulin sensitivity. Identifying the molecular mechanisms by which these medications improve glucose homeostasis can help us to develop newer forms of SGLT2i with lesser side effects. We have reviewed the molecular mechanisms and signaling pathways by which SGLT2i therapy improve insulin sensitivity and ameliorates insulin resistance.
|Journal Article Type||Article|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Yaribeygi, H., Sathyapalan, T., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2020). Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sciences, 240, https://doi.org/10.1016/j.lfs.2019.117090|
|Keywords||Sodium-glucose co-transporter-2 inhibitors; Insulin sensitivity; Insulin resistance; Diabetes mellitus; Oxidative stress; Inflammatory response|
|Additional Information||This article is maintained by: Elsevier; Article Title: Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review; Journal Title: Life Sciences; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lfs.2019.117090; Content Type: article; Copyright: © 2019 Published by Elsevier Inc.|
This file is under embargo due to copyright reasons.
Contact T.Sathyapalan@hull.ac.uk to request a copy for personal use.
You might also like
Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection?
The role of interleukin-18 in the development and progression of atherosclerosis